Allergic rhinitis from the perspective of an allergist
- Authors: Sidorovich O.I.1, Luss L.V.1
-
Affiliations:
- National Research Center - Institute of Immunology
- Issue: Vol 21, No 3 (2019)
- Pages: 75-78
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/96907
- DOI: https://doi.org/10.26442/20751753.2019.3.190290
- ID: 96907
Cite item
Full Text
Abstract
Allergic rhinitis (AR) is the most common allergic disease. Rational drug therapy should be aimed at nonspecific suppression of the clinical symptoms of AR without taking into account the properties of the allergen. Histamine is the main mediator of allergic inflammation. Fexofenadine is an effective H1-antihistamine and a drug of choice for the treatment of all kinds of AR.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Olga I. Sidorovich
National Research Center - Institute of Immunology
Email: olga_smail@yahoo.com
Cand. Sci. (Med.), Senior Res. Officer Moscow, Russia
Liudmila V. Luss
National Research Center - Institute of ImmunologyD. Sci. (Med.), Full Prof. Moscow, Russia
References
- Scadding G.K, Kariyawasam H.H, Mirakian R et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy 2017; 47: 856-89.
- Аллергология. Федеральные клинические рекомендации. Гл. ред. Р.М.Хаитов, Н.И.Ильина. М.: Фармарус Принт Медиа, 2014.
- Brożek J.L, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines - 2016 Revision. J Allergy Clin Immunol 2017; 140 (4).
- Лусс Л.В., Сидорович О.И. Аллергический ринит и аллергический конъюнктивит: механизм взаимосвязи и тактика лечения. Астма и аллергия. 2015; 1: 31-4.
- Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: 147-334.
- Church M, Church D. Pharmacology of antihistamines. Indian J Dermatol 2013; 58: 219-24.
- Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус принт, 1998.
- Holgate S.T, Canonica G.W, Simons F.E et al. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003; 33: 1305-24.
- Axelrod D, Bielory L. Fexofenadine hydrochloride in the treatment of allergic disease: a review. J Asthma Allergy 2008; 1: 19-29.
- Hoechst Marion Roussel. Fexofenadine prescribing information. Kansas City, Missouri, USA.
- Pratt C.M, Mason J, Russell T et al. Cardiovascular safety of fexofenadine HCl. Am J Cardiol 1999; 83: 1451-4.
- Mason J, Reynold R, Rao N. Системная безопасность фексофенадина гидрохлорида. Consilium Medicum. 2000; 2 (5): 202-4
- Howarth P.H, Stern M.A, Roi L et al. Double-blind, placebo-controlled study comparing the efcacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927-33.
- Ciprandi G, Cosentino C, Milanese M et al. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy 2001; 56: 1068-70.
- Simpson K, Jarvis B. Fexofenadine: A Review of its Use in the Management of Seasonal Allergic Rhinitis and Chronic Idiopathic Urticaria. Drugs 2000; 59 (2): 301-21.
- Efficacy and safety profile of fexofenadine HCI: A unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol 2003; S69-S77.
- Инструкция по медицинскому применению препарата Фексадин®.
Supplementary files
